Official Title A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)

Purpose

The purpose of this study is to see if benralizumab (biologic drug), given as injections under the skin, can help control your Hypereosinophilic Syndrome (HES) better if it is added to available standard of care HES medications which you may be currently taking. 

HES (Hypereosinophilic Syndrome) is a disease characterized by high levels of eosinophils (a particular type of white blood cell) in your blood and a build-up of eosinophils in some organs and tissues (like skin, heart, lungs, intestines or others) causing their dysfunction.

The duration of the study will last 18 months.

Could this study be right for you?

• Eosinophil (a type of white blood cells) count ≥ 1000 cells/μL at screening
• Documented diagnosis of Hypereosinophilic Syndrome (HES)
• History of persistent eosinophilia >1500 cells/μL (at least 2 examinations, interval ≥1 month)
• End organ manifestations attributable to the eosinophilia

Inclusion and Exclusion Criteria varies, please contact Study Coordinator for more information.

Age Range

18 years and up

Official Title BUckeye Concussion Knowledge Survey (BUCKS)

Purpose

The purpose of this study is to examine health outcomes in former Ohio State University athletes who played a varsity sport during their time at OSU. The objective is to determine whether athletes who sustained a concussion have different health outcomes than those who did not sustain a concussion. Any former OSU varsity athlete can participate in a 20-minute online survey.

Could this study be right for you?

• Anyone who has played a varsity sport as an undergraduate student at OSU, and they have now graduated (i.e., OSU athlete alumni). There are no other restrictions in terms of age, sex/gender, type of sport, etc.

Age Range

18 years and up

Official Title Mobile Health App as a Cardiotoxicity Symptom Logging Tool: Feasibility Pilot Study

Purpose

To evaluate the cardio-oncology patient population’s experience with using smart-phone technology as a part of self-management with their care through features such as symptom logging and education. Eligible patients will be asked to participate in a 30-minute virtual interview and/or a 60-minute virtual design or usability session to discuss their thoughts on a mobile app for cardio-oncology patients.

Could this study be right for you?

• English-speaking
• Prior cancer diagnosis
• Currently undergoing a cancer regimen that includes a targeted, biologic, radiation, and/or immune-based therapy (e.g., TKIs and/or ICIs).
• No pregnant females
• No prisoners

Age Range

18 and up